Alen Xuring

$GNS $VOCL $NWBO

[Alen Xuring @AXuring2]

$NWBO pin this tweet 👇

[Chad Oltman @OltmanChad]

$NWBO

[Amanda Hollensbe (Braelyn’s Mom) @HollensbeAmanda]

🇺🇸❤️ WE MET PRESIDENT TRUMP TONIGHT! ❤️🇺🇸

What an extraordinary evening for our family!

Tonight, Braelyn, Ben, and I had the incredible opportunity to meet President Trump at the rally in Pendleton, South Carolina!

We had only about 20–30 seconds with him, and I knew I needed to make every second count.

I introduced him to Braelyn and thanked him for telling Dr. Oz about her brain cancer story.

I explained that Braelyn had been diagnosed with glioblastoma, the deadliest type of brain tumor, but that today she is CANCER-FREE after receiving DCVax-L, a personalized cancer vaccine developed right here in America!

Yet we must travel all the way to England for her ongoing treatments because we cannot access it here in the United States.

Then something pretty cool happened!

President Trump turned to one of his staffers and instructed them to get me in touch with Dr. Oz!

I also expressed my hope that we could connect with Secretary Kennedy.

As our brief time together came to an end, I made one final appeal:

“Please help bring this American-made treatment back home to America.”

President Trump was incredibly gracious to our family and very kind to Braelyn. We are so grateful for the opportunity to speak with him!

Earlier in the evening, I was also able to give a member of his staff a detailed packet about Braelyn’s journey, DCVax-L, and the obstacles American patients face in accessing promising investigational treatments.

Now we are praying that the connection with Dr. Oz comes through!

Three years ago, Braelyn was given just months to live. Today, she’s 19, attending college, and her latest MRI shows NO EVIDENCE OF DISEASE RECURRENCE!

Tonight, we had the opportunity to bring her story directly to the President of the United States. ❤️

My prayer is that this opens the door to a much bigger conversation—one that could change the future for countless American cancer patients.

📸 We were not permitted to bring our phones into the private meeting with President Trump, so we couldn’t take our own pictures with him. His staff took an official photograph of us together, which we’re told will be emailed to us. I can’t wait to share it! In the meantime, here are some pictures from our unforgettable evening.

Thank you to EVERYONE who helped make tonight possible and to all of you who continue to share Braelyn’s story. You helped us get this far, and we’re not stopping now! ❤️🙏

@realDonaldTrump @DrOzCMS @WhiteHouse

#DCVaxForBraelyn #DCVax

[Ida Bogac @albtur_mnymkrs]

A 20 year glioblastoma survivor treated with #dcvax will be speaking on Capitol Hill next week at the Parker Institute’s Congressional Briefing on Cancer Vaccines. $NWBO is officially in the same conversation as some of the most prominent cancer vaccine institutions in the world

[Hoffmann @hoffmann6383]

➡️A Settlement

$NWBO

The Case: Northwest Biotherapeutics, Inc v. Canaccord Genuity LLC, 1:22-cv-10185, (S.D.N.Y.)

The Docket: https://t.co/iDEMFp4mge

Recall, when I stated Canaccord Genuity was selling their market making division to Cantor and that could lead to a settlement as they would want to clean up before selling? See:

https://t.co/ER1V0PVLna

Well, it happened. Just like TD settled their spoofing lawsuit prior to their Schwab sale. Here is $NWBO's recent court filing showing they have reached a settlement with Canaccord Genuity:

See attached image.

This should give $NWBO an infusion of cash. As a public company we should keep an eye on upcoming 10Q/10K filings to get an idea of the settlement amount.

[DrewDiligence ✡️🪬 @KarmaCollects]

$MMTLP What a crock of BS. The SEC Just Greenlit the DELETION of ALL Consolidated Audit Trail (CAT) Data Older Than 3 Years

For years, MMTLP shareholders have been demanding access to historical CAT data to expose what we believe was systemic naked shorting, illegal order flow, and market manipulation that wiped out billions in retail value when our shares were forcibly converted/delisted. We’ve been stonewalled at every turn. FOIAs ignored. Congression inquiries ignored. Brokers hiding behind “proprietary” excuses. Now the SEC just handed Wall Street the ultimate get-out-of-jail-free card.

From this press release (March 27, 2026):
“delete certain CAT data, including all CAT data older than three years”

This isn’t “cost savings.” This is legalized destruction of EVIDENCE. The very records that could finally prove our case, or the the SEC could use to DISPROVE US if they are so sure we are wrong - pre-2023 trade data, lifecycle linkages, late-reported trades... are all about to be permanently erased. And @SECPaulSAtkins calls this “progress"?

Well I'm CALLING IT A COVER UP. You are allowing the CAT Plan Participants to purge the data now, and once it’s gone, it’s gone forever. And that, to MMTLP investors, equates to nothing short of Justice denied.

Not legal advice at all, but I wish @JWesChristian would consider filing an emergency injunction RIGHT NOW in U.S. District Court for the District of Columbia (where the SEC is headquartered). This injunction would include a Temporary Restraining Order + Preliminary Injunction against the SEC and the CAT NMS Plan Participants.

Unless I'm wrong, I believe the Administrative Procedure Act could allow one to argue that the rule is “arbitrary and capricious,” violates investor-protection mandates under the Exchange Act, and destroys evidence critical to ongoing private actions and investigations. To be honest, this is right up Wes' alley, and it wouldn't be out of line for him to do so considering that he is special counsel in a bankruptcy proceeding where this data could come into play.

This causes irreparable harm to MMTLP (and other retail) investors who have relied on CAT data for years and there is no adequate remedy at the level of the law once this extremely important data is deleted. Public interest in preserving market transparency as it relates to MMTLP and MMAT (given the ongoing bankruptcy proceeding) outweighs “cost savings” for billion-dollar brokers, when right now this second, that information is EASILY ATTAINABLE.

To be honest, every single affected ticker (every retail victim of old short-selling schemes just got screwed too) should be fighting this. This is not just an MMTLP issue. If they can erase the tape on us, they can erase it on anyone.

We’ve waited years for this information as we've been told time and time again that "there is no problem" without being supplied a single shred of data to back that up. And now, they literally want to burn the very same data? At the very minimum, the CAT data for MMAT, TRCH, and MMTLP should be preserved. Shame on every single entity that lobbied with their money and power in favor of this absolute abomination. This is an affront to the principles at the core of operating a free and fair market.

They should NOT be allowed to delete a SINGLE piece of information that is pertinent to ongoing matters involving theft from the investing public... and this shit is insane.

[The Dapper DO @TheDapperDO]

#NWBO $NWBO

This is not just a collection of vaccine enthusiasts, this is a powerhouse conglomeration of biotech badasses! I was fortunate enough to meet Linda Powers in December (whom I spied in this picture!), but I was unfamiliar with her company here, so I did some digging with the help of AI (disclaimer). Of course, I welcome any corrections in order to properly credit the attendees, their contributions, or otherwise! And these are just from this one screenshot! Imagine all the other participants in a group of almost 100 inspiring leaders in their fields! We #HoldTheLine fighting alongside warriors like these! With cooperation and coordination such as this, I simply cannot wait to see what might be unveiled tomorrow for World Cancer Day!

Advocacy / Coalition Leadership

Laurel Comiter - Senior operations and strategy leader at the Cancer Vaccine Coalition (CVC). She helps coordinate high-level scientific, advocacy, and industry stakeholders to accelerate cancer vaccine development and awareness.

Kristen Dahlgren - Founder & CEO of the Cancer Vaccine Coalition. Former NBC journalist turned cancer-vaccine advocate after her own diagnosis.

Saranne Rothberg - Co-founder of the Cancer Vaccine Coalition and founder of the ComedyCures Foundation. Focuses on patient advocacy, fundraising, and public engagement around cancer innovation.

Cheryl Stamm - Board President of the Cancer Vaccine Coalition. Governance, funding strategy, and long-term institutional backing for vaccine advocacy.

Scientific & Academic Heavyweights (Core Vaccine / Immunology)

Cornelis (Cees) Melief - One of the founding fathers of therapeutic cancer vaccines. Pioneered dendritic-cell and T-cell–based vaccine strategies. Legendary figure in tumor immunology.

Catherine Wu - Dana-Farber oncologist and global leader in personalized neoantigen cancer vaccines (e.g., NeoVax). Her work underpins many mRNA and peptide vaccine strategies.

Mary L. 'Nora' Disis - Director of the Cancer Vaccine Institute at UW. Pioneer in HER2/neu and tumor-antigen vaccines in breast and ovarian cancer. Central architect of the modern cancer-vaccine field.

Glenn Dranoff - Harvard/Dana-Farber immunologist known for GM-CSF–based cancer vaccines. His work laid foundational principles still used in today’s platforms.

Pawel Kalinski - Specialist in next-generation dendritic-cell vaccines and immune-polarization strategies to improve clinical responses.

Hideho Okada - UCSF neurosurgeon-scientist developing brain tumor vaccines and T-cell therapies, especially for glioblastoma.

Clinical Trial & Translational Oncology Leaders

Paolo A. Ascierto - World-renowned melanoma immunotherapy clinician. While best known for checkpoint inhibitors, his work directly intersects with therapeutic cancer vaccines.

Brian Czerniecki - Surgeon-scientist who has led dendritic-cell breast cancer vaccine trials, including preventive strategies.

Marina Baretti - Johns Hopkins oncologist involved in clinical cancer vaccine trials, particularly rare GI and liver cancers.

Tom Budd - Cleveland Clinic oncologist and principal investigator on breast cancer vaccine studies.

H. Kim Lyerly - Duke surgeon-scientist and former Cancer Center director. Deeply involved in translating immunology into clinical cancer treatments, including vaccines.

Industry, Biotech & Capital Enablers

Linda Powers - CEO of Northwest Biotherapeutics, developer of DCVax dendritic-cell immunotherapy platforms. Represents real-world commercialization of personalized cancer vaccines.

Katherine Andersen - Senior leader at HSBC Innovation Banking. Provides the capital infrastructure required to scale cancer-vaccine biotech companies.

Scientific Institutions & Conveners

Michael Powell - Senior American Association for Cancer Research (AACR) leader. Helps organize scientific working groups and cross-institution collaboration.

Sean Malvey - AACR media/production lead. Responsible for disseminating and recording high-level scientific discourse — crucial for institutional visibility and education.

Additional Participants

Tony Ng - King’s College London cancer researcher with strong ties to translational oncology and drug development, often overlapping with immunotherapy ecosystems.

Mitch Levine - Appears to be a senior oncology advisor/industry participant. Not a frontline vaccine scientist, but likely contributes regulatory, strategic, or institutional expertise.

Samir (likely Samir Khleif) - Physician-scientist known for tumor immunology and cancer vaccine strategy, formerly involved in national-level cancer immunotherapy initiatives.

Stephen (host/moderator – limited public info)
Appears to be a meeting facilitator or allied contributor rather than a vaccine scientist.

[Gregory Zivic, MD @metacollectiveG]

$NWBO Great news here. This is proof of how legitimate #DCVax is becoming. All things are moving in our direction. Northwest Bio is the only named company in the article https://t.co/LehXNygHi2

[The Dapper DO @TheDapperDO]

I do wonder how much @elonmusk has heard of the cancer breakthrough miracle that is #NWBO and #DCVax ! He could do a world of good in support of it!

[Alen Xuring @AXuring2]

@hoffmann6383 If it's possible to just run out the clock, then how can they ever be forced(?) to comply? What's the penalty for noncompliance? I.e. running out the clock and submitting minimal/insubstantial documents?

[Alen Xuring @AXuring2]

ahem... $NWBO

"It's gonna be very, very hard, in this day and age, to find companies where you can actually buy it for less than the actual value."

https://t.co/4JHwEahBPB

[Michael Miller @Michael48826289]

The Squeeze: If NWBO is one of the first companies to use this new regime tomorrow, it would signal an immediate transition from the manipulated OTC to the highly regulated LSE Main Market.

[🇩🇰 The Danish Dude 🇬🇱 @FlemmingBruce]

$NWBO

Post 1/2

Thanks to @ATLnsider for this research which I will try to dig into.

https://t.co/cEnWPhDGcQ

The Hidden "Cure" Trade in $NWBO

Most investors are watching Northwest Biotherapeutics for one thing:

the DCVax-L approval for brain cancer (GBM). While that is huge, it’s missing a much bigger picture that has quietly developed in the background.

$NWBO has secured the rights to a next-generation technology that is currently curing "incurable" Stage 4 breast cancer in human trials.

This isn't a mouse study. It’s happening right now in patients.

In June 2024, NWBO announced an exclusive worldwide license with Roswell Park Comprehensive Cancer Center. This deal gave them control of the "Alpha-DC1" platform developed by Dr. Pawel Kalinski and Dr. Brian Czerniecki.

Why does this matter? Because a recent patient case at Moffitt Cancer Center—using this exact method - just provided what looks like a "functional cure" for metastatic disease.

If you are only valuing $NWBO on GBM, you are getting a free call option on a multi-billion dollar breast cancer franchise.

Here is the breakdown of the "Dallas Carroll" signal and why it changes the investment thesis.

The "Dallas Carroll" Signal - Proof of Concept

To understand the value of the asset NWBO bought, look at the patient data coming out of Moffitt Cancer Center.
Dallas Carroll was a young mother diagnosed with Stage 4 HER2-positive breast cancer. It had spread (metastasized) to her liver and bones. In standard oncology, this is a terminal diagnosis.

You don't cure it; you just try to extend life by a few years with chemo.

She enrolled in a trial led by Dr. Brian Czerniecki - Dr. Kalinski’s long-time partner and co-inventor of the tech NWBO licensed.

The treatment was different. Instead of just injecting a vaccine into the skin, they injected these "Alpha-DC1" dendritic cells directly into her breast tumor.

The result?

The immune system woke up. It didn't just attack the breast tumor; it hunted down the cancer in her liver and bones and cleared them out.

18 months later, she is cancer-free (No Evidence of Disease). Surgeons were able to remove the primary mass and found the cancer was dead.

This is called the "Abscopal Effect" - treating one spot to cure the whole body. This is the Holy Grail of cancer treatment, and NWBO now owns the rights to the platform that achieved it.

How It Works

Why did this work when other vaccines failed?

Most solid tumors (like breast cancer) are "Cold." They build a wall around themselves that immune cells can't penetrate. You can have plenty of killer T-cells in your blood, but if they can't get inside the tumor, they are useless.

The technology NWBO licensed (the Kalinski/Czerniecki IP) solves this two ways:

1. The GPS Signal (Chemokines):

The "Alpha-DC1" cells are engineered to release massive amounts of chemical signals. Think of this like dropping a GPS pin inside the tumor that screams "HERE!" to the immune system. It physically pulls killer T-cells out of the blood and into the tumor.

2. The Training:

Once the T-cells arrive, the vaccine trains them to recognize the specific "scent" of the cancer.

Because they injected it directly into the tumor, the immune system learned to recognize the cancer at the source. Those trained cells then traveled through the blood to scrub the liver and bones clean.

This effectively turns the patient's own tumor into its own vaccine factory.

[ATLnsider @ATLnsider]

Thanks to Lykiri on IHub, things seem to be progressing forward in the UK with $NWBO MAA for #DCVax-L as it was considered in the November CHM meeting:

[🇩🇰 The Danish Dude 🇬🇱 @FlemmingBruce]

$NWBO

Now you can download the FULL Transcript of Al Musella webinar December 5th. 2022 with UCLA doctor Linda Liau.

AND FINALLY

… with the missing Q&A section 💪🏻

https://t.co/6QOFtWvcjz

Thanks @AlMusella 🙏🏻

[Alen Xuring @AXuring2]

@StonkMasterJ @tommba @TommyBaxendale can you share screenshots?

[Alen Xuring @AXuring2]

$NWBO

The system is being staged for a public release. These brief appearances are often referred to as "ghosting" or 'staging errors" in regulatory publishing systems, where data is pushed live before the official press release or front-end website is updated. --Gemini

[StonkMaster @StonkMasterJ]

$NWBO

Check out @TommBa message on Stocktwits https://t.co/LeWA9gM9tx

🧐🧐🧐

[🇩🇰 The Danish Dude 🇬🇱 @FlemmingBruce]

$NWBO

This is Linda Powers.

If she didn’t needed help the last decade, she doesn’t need it now.

Watch and learn.

[Alen Xuring @AXuring2]

For those who may not know... It's not just $NWBO... It's whole *market* manipulation. And the scum *will* pay 💰💰💰

[Roger James Hamilton @rogerhamilton]

On the 3 year anniversary of the $MMTLP U3 halt, thank you to @johnbrda, @palikaras and the $MMTLP community for educating CEOs like me on the mechanics of market manipulation, what it means to fight with facts, and to never, never give up. We'll keep fighting for fair markets as long as it takes.

[Lou Smith 🍀 @smith348572]

Here is the most logical, evidence-based explanation for why market makers are keeping $NWBO share price extremely low and why this behavior is the opposite of normal market dynamics.

✅ The #1
Most Logical Reason: They Cannot Allow the Price to Rise Before Approval

This is the core reasoning that explains EVERYTHING.

If $NWBO has (imho):
•2B+ synthetic / naked short shares
•MHRA approval appears almost certain, with a 95% probability

then any significant rise in the price before the approval would trigger:

→ Margin calls

→ Buy-ins

→ Collateral requirements jumping

→ A forced short squeeze BEFORE the news

This would be catastrophic before they even get to the real danger: approval.
They must keep the price flat or lower to survive until the announcement.

✅ Reason #2
They need liquidity to escape if the worst happens

If approval arrives:

MM’s and hedge funds with synthetic shorts will need:
•massive volume
•massive retail/institutional buying
•massive price movement
to cover or partially cover.

BUT they cannot create that volume now.

So the goal is:
Keep the stock boring, flat, and unattractive.

Avoid volume.
Avoid buyers.

Because if big money steps in early, it steals the liquidity needed for them to escape later.

✅ Reason #3
They are avoiding “price discovery” before the approval

Remember this:
$NWBO is not trading based on its company value.
It trades based on short liabilities.

If price discovery happened today, the stock would instantly price in:
•UK approval probability
•GBM market
•Sawston’s MIA
•Flaskworks
•the lawsuit
•institutional entry
•partnership potential
•global regulatory follow-on approvals

Basic biotech math says NWBO’s pre-approval fair value is $2–$4.

But if the price rises now real price discovery = margin calls = forced covering.

So they prevent price discovery by:
•spoof walls
•dark pool volume
•hit pieces
•walking the bid
•grinding charts to discourage buyers

✅ Reason #4
They are defending a “synthetic short pyramid”

In a synthetic short structure, each additional synthetic share requires another layer of hedging.

If the stock rises:
•the hedges explode in cost,
•the options offsets become invalid,
•the synthetic chain collapses.

This creates a pyramid structure that must stay stable until the binary event (approval).